Filing Details

Accession Number:
0001209191-22-047760
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-08-26 19:29:59
Reporting Period:
2022-08-24
Accepted Time:
2022-08-26 19:29:59
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1599901 Avidity Biosciences Inc. RNA Pharmaceutical Preparations (2834) 461336960
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1629383 Sarah Boyce C/O Avidity Biosciences, Inc.
10578 Science Center Drive, Suite 125
San Diego CA 92121
President And Ceo Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2022-08-24 35,045 $1.24 35,045 No 4 M Direct
Common Stock Disposition 2022-08-24 35,045 $22.80 0 No 4 S Direct
Common Stock Acquisiton 2022-08-25 14,855 $1.24 14,855 No 4 M Direct
Common Stock Disposition 2022-08-25 14,855 $23.07 0 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2022-08-24 35,045 $0.00 35,045 $1.24
Common Stock Stock Option (Right to Buy) Disposition 2022-08-25 14,855 $0.00 14,855 $1.24
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
1,161,870 2029-12-17 No 4 M Direct
1,147,015 2029-12-17 No 4 M Direct
Footnotes
  1. The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
  2. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $22.45 to $23.05.The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $22.84 to $23.42.The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  4. 25% of the shares subject to the option vested on October 7, 2020 and 1/48th of the shares subject to the option will vest monthly thereafter.